clinical trial · NCT02187003
Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
Anemia, Sickle CellRivipanselPlacebo
brief summary
This is a clinical study evaluating the efficacy and safety of rivipansel (GMI-1070) in treating subjects with sickle cell disease (SCD) who are 6 years of age or older experiencing a pain crisis necessitating hospitalization.
started
Jun 17, 2015
primary completion
May 3, 2019
completion
Jun 27, 2019
last updated
Mar 11, 2025
official title
A Phase 3, Multicenter ,Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol